Company Overview

IN8bio, Inc. is a clinical-stage biotechnology company focused on developing gamma-delta T cell-based immunotherapies for cancer and other difficult-to-treat diseases. The company operates within the biotechnology and cell therapy industries, with research centered on leveraging the immune system’s innate and adaptive capabilities to target tumors. IN8bio’s primary development programs involve allogeneic and autologous gamma-delta T cell therapies intended for hematologic malignancies and solid tumors, including glioblastoma and acute leukemia. Its core revenue activity currently derives from research and development operations rather than commercial product sales, as the company remains in the clinical development stage.

The company traces its origins to work conducted around gamma-delta T cell biology and was incorporated as IN8bio before becoming publicly traded on the Nasdaq under the ticker INAB. IN8bio has positioned itself around proprietary approaches designed to enhance the persistence and tumor-targeting activity of gamma-delta T cells while potentially reducing graft-versus-host disease risks associated with certain conventional cell therapies. The company’s strategy emphasizes differentiated immunotherapy platforms targeting areas with high unmet medical need.

Business Operations

IN8bio organizes its operations primarily around the research, development, and clinical advancement of its gamma-delta T cell therapy pipeline. Its major therapeutic programs include investigational candidates such as INB-100, INB-200, and other gamma-delta T cell platforms targeting cancers including glioblastoma and hematologic malignancies. The company’s operating activities are concentrated in clinical development, manufacturing coordination, regulatory engagement, and translational research. Revenue generation has historically been limited and primarily associated with collaboration-related activities and financing transactions rather than recurring commercial operations.

The company conducts operations primarily in the United States, while also engaging with international manufacturing, research, and clinical collaborators as required for biotechnology development. IN8bio controls proprietary intellectual property related to gamma-delta T cell expansion and therapeutic application technologies. The company has also collaborated with academic institutions and clinical centers to support trials and translational studies. As a clinical-stage biotechnology company, its operational model depends heavily on capital markets financing, research partnerships, and regulatory progression.

Strategic Position & Investments

IN8bio’s strategic direction centers on advancing gamma-delta T cell therapies as a differentiated immunotherapy platform capable of addressing limitations associated with traditional alpha-beta T cell approaches. The company has prioritized clinical programs in glioblastoma and leukemia, particularly where existing treatment options remain limited and survival outcomes are poor. Its development strategy includes evaluating combination therapies, optimizing cell manufacturing processes, and expanding clinical data supporting the safety and efficacy of gamma-delta T cells.

The company has invested significantly in research infrastructure, intellectual property development, and clinical trial expansion. IN8bio’s portfolio includes investigational therapies designed for both autologous and allogeneic applications, reflecting broader industry interest in scalable cellular immunotherapy platforms. The company also operates within emerging sectors of oncology focused on engineered immune-cell therapeutics, precision immunotherapy, and next-generation cell therapy manufacturing technologies. Public disclosures and regulatory filings indicate continued emphasis on advancing late-stage clinical evidence and strengthening its therapeutic platform.

Geographic Footprint

IN8bio is headquartered in New York, United States, and its primary operational footprint is concentrated in the U.S. biotechnology and clinical research ecosystem. The company’s clinical development activities involve collaborations with medical institutions, cancer centers, and research organizations across multiple U.S. regions. Its regulatory and investor engagement activities are also primarily U.S.-focused due to its Nasdaq listing and reporting obligations.

Although IN8bio does not maintain the broad multinational commercial infrastructure associated with large pharmaceutical companies, it participates in the global biotechnology sector through research partnerships, clinical development networks, and manufacturing relationships that may involve international participants. Its strategic and operational influence is most visible within the North American oncology and immunotherapy markets, though the scientific relevance of gamma-delta T cell therapy has broader international applicability.

Leadership & Governance

IN8bio’s leadership team is led by executives with backgrounds in biotechnology, immunotherapy, oncology research, and corporate development. The company’s governance structure follows standard U.S. public-company practices, including oversight by a board of directors and reporting obligations under SEC filings and Nasdaq corporate governance requirements. Leadership communications have consistently emphasized advancing gamma-delta T cell science into clinically validated therapeutic products while maintaining disciplined capital allocation and regulatory execution.

Key executives include:

• William Ho – Co-founder and Chief Executive Officer
• Lewis H. Bender III – President
• David P. Bersch – Chief Financial Officer
• Sandra Silvestri – Chief Regulatory Officer
• Mark A. Frattini, M.D., Ph.D. – Chief Medical Officer

The company’s leadership philosophy has focused on translating academic and translational immunology research into scalable therapeutic programs, with strategic emphasis on oncology innovation, clinical validation, and long-term platform development.